Fatemeh Lorenz-Salehi
Helios Dr. Horst Schmidt Kliniken Wiesbaden(DE)
Publications by Year
Research Areas
Breast Cancer Treatment Studies, Advanced Breast Cancer Therapies, HER2/EGFR in Cancer Research, Cancer Treatment and Pharmacology, Cancer Genomics and Diagnostics
Most-Cited Works
- → West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment(2016)361 cited
- → Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases(2009)221 cited
- → Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial(2017)187 cited
- → West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer(2019)145 cited
- → Mastectomy trends for early-stage breast cancer: A report from the EUSOMA multi-institutional European database(2012)111 cited
- → Cerebral metastases in metastatic breast cancer: disease-specific risk factors and survival(2010)50 cited
- → Time trends (2006–2015) of quality indicators in EUSOMA-certified breast centres(2017)36 cited
- → Prognostic Factors for Local, Loco-regional and Systemic Recurrence in Early-stage Breast Cancer(2015)18 cited
- → Prospective WSG phase III PlanB trial: Final analysis of adjuvant 4xEC→4x doc vs. 6x docetaxel/cyclophosphamide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer.(2017)16 cited
- → Additional prognostic value of lymph node ratio over pN staging in different breast cancer subtypes based on the results of 1,656 patients(2014)10 cited